Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety of pimecrolimus Cream 1% with topical corticosteroid treatment (commonly used in eczema) in patients with severe atopic dermatitis.

Inclusion Criteria:

• Severe atopic dermatitis
• 5% of total body surface area (TBSA) affected

Exclusion Criteria:

• Concurrent skin diseases (infections)
• Immunocompromised
• Recently received phototherapy or systemic therapy